CNS Pharmaceuticals, Inc. announced the presentation of updated safety data from the ongoing potentially pivotal study evaluating Berubicin, the company's novel anthracycline and the first anthracycline to appear to cross the blood-brain barrier, in a poster presentation at the SNO 28th Annual Meeting, held November 15-19, 2023 in Vancouver, Canada. Summary of Updated Safety Results from the Potentially Pivotal Study: Patient demographics are comparable between each arm, including age, gender, race, body surface area (BSA), andKarnofsky Performance Status Scale (KPS). In addition, patients with unmethylated MGMT comprise approximately 40% of each arm, allowing for comparison irrespective of the molecular profile that might influence the efficacy of the therapy administered.

Although more patients withdrew from the study in the Lomustine arm than the Berubicin arm, there are too few patients to reach any conclusion about whether this will affect the outcome; All reported adverse events for both arms are shown for all grades and grades 3-5. These were similar, including the more severe events in the higher grades. The adverse events occurring in more than 10% of patients and/or that were considered treatment-related, are shown for all grades as well as grades 3-5, and overall were relatively similar in the Berubicin and Lomustine arms. In terms of myelosuppression (lymphocyte, neutrophil/white blood cell count or red blood cell [anemia] reductions), there is no significant difference between the therapeutic arms, although thrombocytopenia (platelet count decrease) appears to be slightly greater with Lomustine for all grades of severity as well as grades 3-5.